Mainstream

CEO.CA’s Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

CEO.CA’s Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Toronto, Ontario–(Newsfile Corp. – July 28, 2025) – CEO.CA (“CEO.CA”), the leading…Read More

You might also be interested in reading CrossTower revises new offer for Voyager’s assets after FTX’s bankruptcy.

July 28, 2025
In Mainstream